Edition:
United Kingdom

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.64USD
22 May 2018
Change (% chg)

$-0.03 (-1.80%)
Prev Close
$1.67
Open
$1.66
Day's High
$1.66
Day's Low
$1.62
Volume
3,229
Avg. Vol
225,642
52-wk High
$8.37
52-wk Low
$0.65

Select another date:

Wed, May 9 2018

BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA

* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE

BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease

* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE

BRIEF-vTv Therapeutics Says Phase 1B Study Of TTP399 For The Treatment Of Type 1 Diabetes Completed

* VTV THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1B STUDY EVALUATING TTP399 FOR THE TREATMENT OF TYPE 1 DIABETES Source text for Eikon: Further company coverage:

BRIEF-VTV Therapeutics Reports Q4 Loss Per Share $0.44

* VTV THERAPEUTICS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-vTv Therapeutics Files For Stock Shelf Of Up To $250 Million

* VTV THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION – SEC FILING‍​ Source text for Eikon: (http://bit.ly/2EUHrux) Further company coverage:

BRIEF-Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement

* VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM

BRIEF-vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program

* VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM

BRIEF-VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes

* VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING

Select another date: